JP2017513944A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513944A5 JP2017513944A5 JP2017505684A JP2017505684A JP2017513944A5 JP 2017513944 A5 JP2017513944 A5 JP 2017513944A5 JP 2017505684 A JP2017505684 A JP 2017505684A JP 2017505684 A JP2017505684 A JP 2017505684A JP 2017513944 A5 JP2017513944 A5 JP 2017513944A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- apc
- skin area
- scar
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 11
- 231100000241 scar Toxicity 0.000 claims 5
- 230000001575 pathological effect Effects 0.000 claims 2
- 108700025721 3K3A-APC Proteins 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014901397 | 2014-04-16 | ||
| AU2014901397A AU2014901397A0 (en) | 2014-04-16 | Treatment of abnormal cutaneous scarring | |
| PCT/AU2014/050323 WO2015157791A1 (en) | 2014-04-16 | 2014-10-29 | Treatment of abnormal cutaneous scarring |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019179634A Division JP6846063B2 (ja) | 2014-04-16 | 2019-09-30 | 異常な皮膚瘢痕化の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017513944A JP2017513944A (ja) | 2017-06-01 |
| JP2017513944A5 true JP2017513944A5 (enExample) | 2017-11-24 |
Family
ID=54323254
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505684A Pending JP2017513944A (ja) | 2014-04-16 | 2014-10-29 | 異常な皮膚瘢痕化の治療 |
| JP2019179634A Active JP6846063B2 (ja) | 2014-04-16 | 2019-09-30 | 異常な皮膚瘢痕化の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019179634A Active JP6846063B2 (ja) | 2014-04-16 | 2019-09-30 | 異常な皮膚瘢痕化の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170042982A1 (enExample) |
| EP (1) | EP3137102B1 (enExample) |
| JP (2) | JP2017513944A (enExample) |
| CN (1) | CN106573040B (enExample) |
| AU (1) | AU2014391082B2 (enExample) |
| CA (1) | CA2946028C (enExample) |
| DK (1) | DK3137102T3 (enExample) |
| ES (1) | ES2890675T3 (enExample) |
| PL (1) | PL3137102T3 (enExample) |
| PT (1) | PT3137102T (enExample) |
| WO (1) | WO2015157791A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104394883B (zh) * | 2012-07-04 | 2017-05-31 | 悉尼大学 | 炎性皮肤病症的治疗 |
| US20170035862A1 (en) | 2014-04-16 | 2017-02-09 | Zz Biotech Llc | Use of APC analogue for wound healing |
| CA3134041A1 (en) * | 2019-03-19 | 2020-09-24 | Figene, Llc | Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof |
| CN113073082A (zh) * | 2021-03-19 | 2021-07-06 | 广州远想生物科技有限公司 | TGF-β3间充质干细胞外泌体及其制备方法和应用 |
| CN114788711A (zh) * | 2022-04-26 | 2022-07-26 | 李娜 | 一种瘢痕评估方法及系统 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US5516650A (en) | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| US4959318A (en) | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
| EP0380508A4 (en) | 1987-05-18 | 1991-04-03 | Integrated Genetics, Inc. | Improved protein c molecules and method for making and activating same |
| US5084274A (en) | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
| US4981952A (en) | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
| US5093117A (en) | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
| AT402260B (de) | 1990-08-16 | 1997-03-25 | Immuno Ag | Protein c-hältige pharmazeutische präparation |
| US5571786A (en) | 1990-08-16 | 1996-11-05 | Immuno Aktiengesellschaft | Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation |
| AT397615B (de) | 1991-05-14 | 1994-05-25 | Immuno Ag | Arzneimittel enthaltend protein c |
| WO1993009807A1 (en) | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels |
| MY110664A (en) | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| DE4239150A1 (de) | 1992-11-20 | 1994-05-26 | Thomae Gmbh Dr K | O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
| JP3043558B2 (ja) | 1993-10-29 | 2000-05-22 | 財団法人化学及血清療法研究所 | ヒト活性化プロテインｃ調製物及びその製法 |
| AU2467395A (en) | 1994-05-04 | 1995-11-29 | Board Of Trustees Of The University Of Arkansas, The | Novel ophthalmologic uses of protein c |
| PL195642B1 (pl) | 1997-04-28 | 2007-10-31 | Lilly Co Eli | Sposób przetwarzania wodnego roztworu aktywowanego białka C |
| HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| WO2001056532A2 (en) | 2000-02-04 | 2001-08-09 | The Scripps Research Institute | Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| AU2001232799A1 (en) | 2000-02-11 | 2001-08-20 | Eli Lilly And Company | Protein c derivatives |
| ES2242740T3 (es) * | 2000-03-28 | 2005-11-16 | Eli Lilly And Company | Proteina c activada para el tratamiento de pancreatitis. |
| AU1038802A (en) * | 2000-10-18 | 2002-04-29 | Maxygen Aps | Protein c or activated protein c-like molecules |
| ES2384099T3 (es) * | 2001-06-13 | 2012-06-29 | The University Of Sydney | Proteína C para cicatrización de heridas |
| WO2004041296A2 (en) | 2002-11-06 | 2004-05-21 | Novo Nordisk A/S | Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides |
| EP1477166B1 (de) * | 2003-04-28 | 2006-08-23 | Biofrontera Bioscience GmbH | Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis |
| US9192657B2 (en) | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| WO2005007820A2 (en) * | 2003-07-08 | 2005-01-27 | The Scripps Research Institute | Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| US20070224150A1 (en) | 2005-03-24 | 2007-09-27 | Yongji Chung | Growth factor for hair and skin treatment |
| CN101262880A (zh) * | 2005-06-24 | 2008-09-10 | 德拉格雷丘尔公司 | 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物 |
| GR1005700B (el) | 2006-09-01 | 2007-10-22 | (40%) ����� �������� | Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα |
| CA2668187A1 (en) * | 2006-10-31 | 2008-06-19 | The Scripps Research Institute | Dosing regimen of activated protein c and variants having reduced anticoagulant activity |
| GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
| ES2316312B1 (es) | 2008-06-20 | 2010-02-08 | Ignacio Umbert Millet | Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas. |
| EP2157176A1 (en) | 2008-08-20 | 2010-02-24 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Protein C Variants |
| CN101912450A (zh) | 2010-09-01 | 2010-12-15 | 吴业刚 | 一种治疗脚气皮炎的中西药组合物及其制备方法 |
| CN104394883B (zh) * | 2012-07-04 | 2017-05-31 | 悉尼大学 | 炎性皮肤病症的治疗 |
| US20170035862A1 (en) | 2014-04-16 | 2017-02-09 | Zz Biotech Llc | Use of APC analogue for wound healing |
-
2014
- 2014-10-29 EP EP14889425.6A patent/EP3137102B1/en active Active
- 2014-10-29 PL PL14889425T patent/PL3137102T3/pl unknown
- 2014-10-29 AU AU2014391082A patent/AU2014391082B2/en active Active
- 2014-10-29 CA CA2946028A patent/CA2946028C/en active Active
- 2014-10-29 CN CN201480078924.1A patent/CN106573040B/zh active Active
- 2014-10-29 JP JP2017505684A patent/JP2017513944A/ja active Pending
- 2014-10-29 ES ES14889425T patent/ES2890675T3/es active Active
- 2014-10-29 US US15/304,446 patent/US20170042982A1/en not_active Abandoned
- 2014-10-29 DK DK14889425.6T patent/DK3137102T3/da active
- 2014-10-29 PT PT148894256T patent/PT3137102T/pt unknown
- 2014-10-29 WO PCT/AU2014/050323 patent/WO2015157791A1/en not_active Ceased
-
2018
- 2018-10-09 US US16/155,475 patent/US20190060421A1/en not_active Abandoned
-
2019
- 2019-09-30 JP JP2019179634A patent/JP6846063B2/ja active Active
- 2019-12-11 US US16/710,387 patent/US11491214B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515522A5 (enExample) | ||
| MX380147B (es) | Formas de dosificacion de ruxolitinib de liberacion sostenida. | |
| CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| CA2894892A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| MX377340B (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| EA201690962A1 (ru) | Составы | |
| JP2014141525A5 (enExample) | ||
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| JP2016518337A5 (enExample) | ||
| JP2014530840A5 (enExample) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| JP2017513944A5 (enExample) | ||
| EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
| WO2016011297A3 (en) | Methods and related compositions for improved drug bioavailability and disease treatment | |
| JP2017531686A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2013231052A5 (enExample) | ||
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| JP2013523758A5 (enExample) |